Immunogenicity of inactivated subunit adsorbed monovalent vaccine against influenza A/ California/7/2009 (H1N1) strain


Cite item

Full Text

Abstract

The immunogenicity of Pandeflu subunit vaccine against influenza A/California/7/2009 (H1N1) was evaluated in 70 healthy volunteers aged 18 to 60 years. The vaccine was intramuscularly injected twice at an interval of 28 days. Each dose (0.5 ml) contains A(H1N1) influenza virus hemagglutinin (15 ± 2.2 μg), aluminum hydroxide (Denmark) (0.475 ± 0.075 μg), and the preservative thiomerosal (merthiolate) (50 ± 7.5 μg). The level of antibodies was determined in the microneutralization assay. After administration of two doses of the vaccine at a 28-day interval, the geometric mean antibody titer (GMAT) reached 1:21.1 with a further increase to 1:30 (the baseline GMAT) was 1:6.1). The frequencies of seroconversion and seroprotection were 71.4 and 59.2%, respectively; the antibody increase factor was 4.92, which meets the CPMP criteria. The administration of the vaccine did not result in adverse reactions in the postvaccination period.

References

  1. Всемирная организация здравоохранения 2009 г. Безопасность пандемических вакцин. Пандемический грипп (H1N1) - 2009. Краткое сообщение № 89.
  2. Медуницин Н. В. Вакцинология. - 3-е изд. - М., 2010.
  3. Некрасов А. В., Пучкова Н. Г. Стратегия совершенствования и методы оценки гриппозных вакцин. Гриппол плюс - современная защита от гриппа // Рус. мед. журн. - 2008. - № 23 (16). - С. 1-4.
  4. Некрасов А. В., Пучкова Н. Г., Харит С. М. и др. Вакцина Грипол Нео: результаты клинических исследований безопасности и реактогенности (фаза 11) // Эпидемиол. и вакцинопрофилактика. - 2009. - № 5 (48). - С. 54-60.
  5. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека // О внесении изменений в статью 9-го Федерального закона от 17 сентября 1998 № 157-ФЗ "Об иммунопрофилактике инфекционных болезней". - М., 1998.
  6. European Medicines Agency recommends update of product information for Pandemrix to include more data from studies in children. European Medicines Agency. Published 22 January 2010, London.
  7. Grotto I., Engelhard D. The safety and immunogenicity of the vaccines against pandemic (H1N1) 2009 influenza // Harefuah. - 2009. - Vol. 148, N 12. - P. 799-803.
  8. Hirschlen B., Kelland K., Deighton B. EU agency recommends first two H1N1 flu vaccines. Reuters health information. London, 25 sep. 2009.
  9. Immunogenicity tests for Celvapan - outcome of a meeting of vaccination experts. European Medicines Agency. Published 19 February 2010.
  10. Influenza A (H1N1) 2009 Monovalent Vaccines. 2009 Centers for Disease Control and Prevention (CDC) // MMWR Morbid. Mortal. Wkly Rep. - 2009. - Vol. 58, N 39. - P. 1100-1101.
  11. Iskander J., Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience // Expert Rev. Vaccines. - 2008. - Vol. 7, N 1. - P. 75-82.
  12. Kyriakis C. S., Gramer M. R., Barbe F. et al. Efficacy of commercial swine influenza vaccines against challenge with a recent European H1N1 field isolate // J. Vet. Microbiol. - 2010. - Vol. 144. - P. 67-74.
  13. Nicoll A., Ammon A., Amato A. et al. Experience and lessons from surveillance and, studies of the 2009 pandemic in Europe // Publ. Hlth. - 2010. - Vol. 124C, N 1. - P. 14-23.
  14. Safety of influenza A (H1N1) 2009 monovalent vaccines-United States, October 1 - November 24, 2009 Centers for Disease Control and Prevention (CDC)// MMWR Morbid. Mortal. Wkly Rep. - 2009. - Vol. 58, N 48. - P. 1351-1356.
  15. Sindoni D., La Fauci V., Squeri R. et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity // J. Prev. Med. Hyg. - 2009. - Vol. 50, N 2. - P. 121-126.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Zverev V.V., Kostinov M.P., Mikhaylova N.A., Zhirova S.N., Mironov A.N., Terkacheva O.A., Romanova A.A., Cherdantsev A.P., Zverev V.V., Kostinov M.P., Mikhailova N.A., Zhirova S.N., Mironov A.N., Terkacheva O.A., Romanova A.A., Cherdantsev A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies